MetaCap

Praxis Precision Medicines Inc. (PRAX)

NASDAQ: PRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

300.43-10.47 (-3.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRAX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$12.82
52-week range
167.32 – 392.70
Day range
298.54 – 314.15
Volume / Avg
806.14K / 479.87K
Beta
—

52-week range

$167.32$392.70

PRAX stock today

Shares of Praxis Precision Medicines (PRAX) finished lower on Nov 20 at $300.43, a drop of 3.37% or $10.47 per share, versus the S&P 500's 3.70% decline. Shares are 23.5% below their 52-week high of $392.70, set on Aug 20, 2026 and 79.6% above the 52-week low of $167.32, in the middle of the past year's range. PRAX is up 1.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 76.9%.

Praxis Precision Medicines has posted a net loss over the last twelve months (EPS of -$12.82), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Praxis Precision Medicines

Company profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Marcio Silva De'Souza M.B.A.
Headquarters
Boston, MA
Employees
168
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Praxis Precision Medicines generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 7 years shown. Praxis Precision Medicines reported a net loss of $303.3 million, compared with a loss of $182.8 million a year earlier. Diluted earnings per share came in at -$13.48.

Praxis Precision Medicines annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$8.55M$2.45M$0—
Growth-100.00%+249.53%———
Net income$-303.27M$-182.82M$-123.28M$-214.03M$-167.06M
EPS (diluted)$-13.48$-10.21$-18.69$-69.65$-3.94

Analyst forecast

Forecast

Consensus (19 analysts)

strong_buy

Avg. price target

$674.43+124.49%

  • Strong buy 3
  • Buy 15
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $189.00High $1,201.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-3.36 vs $-3.68
Surprise
+8.70%

PRAX news

All PRAX news

Praxis Precision Medicines peers

Health Care sector
PRAX peer companies
CompanyPrice% ChgMarket capCompare
MDGLMadrigal Pharmaceuticals Inc.379.10-4.45%$8.81Bvs PRAX
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs PRAX
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs PRAX
SYRESpyre Therapeutics Inc.93.47-4.26%$8.88Bvs PRAX
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs PRAX
ALKSAlkermes plc44.94-2.69%$7.55Bvs PRAX
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs PRAX
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs PRAX

Indexes, lists and sector

Praxis Precision Medicines stock FAQ

What is Praxis Precision Medicines's stock price today?

PRAX last traded at $300.43 as of Nov 20, 4:00 PM EST, down 3.37% on the day. Prices are delayed at least 15 minutes.

Does Praxis Precision Medicines pay a dividend?

No. Praxis Precision Medicines does not currently pay a regular cash dividend.

Who is Praxis Precision Medicines's CEO?

Mr. Marcio Silva De'Souza M.B.A. is the chief executive officer of Praxis Precision Medicines Inc., which has about 168 employees.

Has PRAX ever split its stock?

Yes. The most recent PRAX stock split was a 1-for-15 split on Nov 29, 2023.

What is the PRAX 52-week high?

The 52-week high for PRAX is $392.70 and the 52-week low is $167.32. The stock is currently 23.5% below its high.

Compare PRAX